RECAF is a molecule that is present on cancer cells but not detected in levels on healthy cells or benign tumor cells.
It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues.
This characteristic makes RECAF an indicator of cancer than other tumor markers.
OncoPet Diagnostics president and BioCurex CEO Ricardo Moro-Vidal said by signing an agreement with UL, they are continuing to extend their distribution area in Asia and look forward to offer their RECAF test, which provides veterinarians with the test to diagnose and treat cancer in companion animals.
"Both in Taiwan and in Korea, the tests will be performed at local laboratories thus ensuring affordable and timely service," Moro-Vidal said.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Alere, formerly Inverness Medical Innovations.
